Open access
Aug 2026
CD44v6- and VEGFR2-targeting antibody-drug conjugates: Enhancing precision and safety in cancer therapy through a dual-targeting strategy.
In mouse xenograft models, the dual-targeting BsADC showed potential anti-tumor activity compared to single-target controls, with no overt body weight loss or observable physical toxicity detected during treatment.
Meng-Huai Wu, Xuezhe Feng, Wen-Qian Huang et al.
· Protein Peptide Letters · 0 citations